Aggregator
Why it will be a ‘painful 2027’ for tech executives, especially Nvidia CEO Jensen Huang
This Dividend Stock Pays You 12 Times a Year. Here's What a $25,000 Investment Deposits Each Month.
This Dividend Stock Pays You 12 Times a Year. Here's What a $25,000 Investment Deposits Each Month.
Todd Piro: Dems are 'going to be a mess the moment they have to start governing'
Global carbon emissions may have peaked in 2026—but only time will tell
Imprint, which helps companies offer co-branded credit cards and manage loyalty programs, raised $130M led by Khosla Ventures at a ~$1.9B valuation (Alex Konrad/Upstarts Media)
Alex Konrad / Upstarts Media:
Imprint, which helps companies offer co-branded credit cards and manage loyalty programs, raised $130M led by Khosla Ventures at a ~$1.9B valuation — Imprint CEO Daragh Murphy's co-branded card startup is now solving loyalty for brands in agentic commerce. — ∙ Paid
People can’t stop trolling AI job ‘interviewers’
AI is conducting job interviews more and more widely. And while it may be anxiety-inducing for some—as they attempt to figure out what a robot deems hirable—others are rage-baiting the technology for the lolz in skits online.
In one recent viral video shared to X, content creator Nick Reid hilariously trolled his AI interviewer, “Karen,” who was seemingly screening him for a job at Burger King—one he clearly didn’t want.
Mind you, Karen isn’t a real BK “employee”: ”We do not use, nor are we aware of any Franchisee across the U.S. or Canada using a tool like this,” Burger King told Fast Company in a comment. But the comedy skit still highlights how awkward interacting with AI bots can be.
And for viewers fed up with the AI revolution, it may be more than a little cathartic to watch.
In the video, which has racked up nearly 8 million views, Reid appears shirtless and with a shoe on his head and introduces himself as Crangeus McBasketball. “Why on Earth do you have a shoe on your head?” Karen replies, while he laughs in her face.
Mr. McBasketball continues to mock the AI by telling it he’s extremely busy and responding to its questions in more and more ridiculous ways. When the AI asks if he would be able to reliably get to shifts at the restaurant, he responds by saying, “Yeah. I have feet.” Karen’s not having it: “That is an incredibly odd way to answer a simple question.”
But this isn’t the only corner of the internet in which “jobseekers” are taking the mickey out of AI avatars. In another video shared to LinkedIn, a man trolls his AI interviewer by speaking utter gibberish. Again, the AI doesn’t mince words.
“This is an absolute waste of my time,” it tells him. “I don’t know if you are having a breakdown or if you simply lack the basic capacity to speak English,” it says.
YouTuber Graham Raabe recently took a swing, too. In a video that now has over 6.3 million views on YouTube and additional ones on X, the creator staged a fake interview with the purpose of pitting two AIs against one another. The creator brings his own bot to the interview, whom he introduces as his “representative,” then excuses himself from the room. Hilarity ensues when the two AIs are left to talk amongst themselves circuitously without an agenda and zero human awareness.
The AI rage-baiting trend is undoubtedly funny. But the comedy videos also sort of demonstrate how sophisticated the AI interviewers actually are.
While there have been some cases of AIs glitching out or getting confused, even when interviewers are purposefully trolling bots, the AIs seem to be responding in a more and more humanlike fashion—like showing frustration with having their time wasted, or recognizing that the candidate is not actually making an effort.
Yet, at the same time, they’re also still far from human; Raabe’s AI “interviewer” and “representative” cross-talked in circles frequently and spent over a minute repeatedly saying goodbye to each other even after Raabe left the room.
Jokes aside, while some find real job interviews with AI to be totally cringe, others actually see its value: According to a 2025 study from the University of Chicago, interviews conducted by AI may actually lead to an increase in job offers. The survey found that AI interviews led to a 12% increase in offers, as well as a 17% increase in 30-day retention.
Of course, many are frustrated with non-human interviews taking off, thus the trend’s emergence in the first place. Candidates often want to connect with an actual human to get a feel for a company, and they also don’t like the fact that AI is replacing so many real people for certain tasks. This comedic content taps into that.
Sure, the real thing may have real benefits. But for those who can’t take the AIs seriously, or are overall fed up with the surge in AI taking over tasks, trolling the bots nobody asked for seems like a spot-on human response.
NYC Ferries are becoming floating classrooms for thousands of students
On weekday mornings, thousands of New Yorkers traverse the city by ferry. Thirty eight boats in the city’s fleet criss-cross the East River, travel up the Hudson, or loop around the bottom of Brooklyn to the Rockaways in order to bring people to work or school. In a city surrounded by water, the ferry is just another way to commute.
But after that morning rush hour, starting in April 2027, some NYC Ferries will be taking on a new task. They’ll transform into floating classrooms, giving the city’s public students an on-the-water, interactive lesson in marine science, the history of the city’s waterways, and what maritime careers could await them.
Those lessons will come from educators with the Billion Oyster Project, a nonprofit that works to restore oyster reefs across New York Harbor and help city residents connect to the water all around them.
“We as New Yorkers have been disconnected by 100 years of danger and pollution and dirtiness from the fact that we are a water town,” says Brian Reagor, director of development at the Billion Oyster Project, which announced the partnership alongside leaders from the NYC Economic Development Council and ferry operator Hornblower Group on Nov. 9 . “[The harbor] is our biggest open space, and yet so few New Yorkers ever come anywhere near it.”
[Photo: Billion Oyster Project] Aquatic lessonsThe 18-year-old Billion Oyster Project has long focused on education alongside its larger goal of restoring one billion oysters back to New York Harbor. It crafts curriculums for city educators, brings workshops into classrooms, and has a partnership with the New York Harbor School on Governors Island, a maritime vocational high school, with parts of the nonprofit’s oyster restoration efforts.
Through these efforts, Billion Oyster Project has taught more than 66,000 students about the Harbor and its inhabitants. But it wants to reach more, and specifically wants to bring more of those kids out onto the water.
Initially, Reagor says, the nonprofit considered buying its own boat, but it quickly realized that would be too expensive. A teacher at the Harbor School brought up partnering with the NYC Ferry. The city’s ferry boats are busy for the morning rush hour, from 7 to 10 a.m. But then ridership drops off.
Last year, the nonprofit approached NYC Ferry, the Hornblower Group (which operates the city’s ferry fleet), and the New York City Economic Development Corporation about using one of those under-utilized boats to take students out on the water.
[Photo: Billion Oyster Project] Getting their sea legsThe floating classrooms will operate on school days from Labor Day to Memorial Day, taking up to two classroom trips per day during off peak hours. That can reach 300 students and teachers daily. The nonprofit’s goal is to bring more than 10,000 public school students onto the harbor annually.
The exact curriculum of the floating classrooms will vary depending on the ferry route. The boats will pick up students and teachers from any of the 25 ferry stops along the harbor and take them on a 90 minute field trip.
The primary goal of the floating classrooms is to simply introduce students to the harbor. “We’re going to talk about the animals that live in the harbor,” Reagor says. “We’re going to talk about the ecosystem and the food web. We’re going to talk about the history of the harbor, how the harbor was the centering point of the city for so many years.”
Students might be surprised to learn, for example, that there are seahorses all throughout the East River. They could meet one on the adventure if they’re lucky, Reagor says. They’ll also learn about the return of dolphins, whales, ospreys, and bald eagles to the harbor. All those animals are the top of the food chain, and they’re back because of efforts to revive oyster reefs.
Workers with the Billion Oyster Project place oysters in the waters near Brooklyn’s Bush Terminal Park, 2018. [Photo: Don Emmert/AFP/Getty Images] Bringing oysters backIn the 1800s, New York clearcut thousands of acres of oyster reef and overharvested the mollusk to the point where it was functionally extinct by the turn of the 20th century. Then, industrialization turned the waterfront into a hotbed of pollution. The 1972 Clean Water Act helped turn things around, and now the water is as clean as it was in the early 1800s. “It’s actually one of America’s and the climate movement’s great success stories,” Reagor says.
That’s allowed oysters to thrive again. Billion Oyster Project has put about 200 million oysters and 19 acres of reef back in the water so far. Oysters filter the water, stabilize the shoreline against climate impacts, increase biodiversity, and create habitats for species like fish, crab, shrimp, and more.
Restoring New York Harbor also restores the image of New York as a water city, one teeming with maritime and environmental careers. New York County alone, which covers Manhattan, is home to 17% of all the marine jobs is the Mid-Atlantic region, according to the NOAA Office for Coastal Management.
Students can get on a marine career path through the Harbor School, a public high school that also offers a free associates degree. More than 50 of the school’s Vessel Operations graduates now work at NYC Ferry as captains or deckhands. But students can get primers on careers in aquaculture, marine biology, ocean engineering, diving professions, coastal sustainability, and more.
The second aim of the floating classroom initiative is to open students’ eyes to those kinds of opportunities. “We’re teaching STEM skills while also showing them a potential vision for their own futures, if they are so inspired,” Reagor says.
But even if students don’t walk away from a floating classroom voyage with the desire to pursue a marine career, that’s okay. “We have at least left you with a better understanding of the environment right outside your door,” Reagor says. “You’ve been on the harbor. It’s not this scary, mythical thing. The idea is making nature, the environment, and climate real to people.”
This new blood test claims to detect more than 50 cancers before the onset of symptoms
Cancer isn’t the leading cause of death in the United States; heart disease ranks first in that regard. But it’s cancer that strikes fear into the hearts of many Americans.
Cancer can take an excruciating toll on its millions of victims and their family members. Cancer treatments are often highly toxic, and the disease is increasingly striking people at younger ages, which is why it accounts for more years of potential life lost than heart disease.
So when a blood test comes along that claims to be able to screen for more than 50 cancers at once in a single blood draw before symptoms appear—as is the case for the Galleri test, by the biotech company GRAIL—it might seem like society has a Holy Grail of modern medicine at their fingertips.
But a closer look at the evidence suggests that the Galleri test is not yet the universal screening breakthrough patients and doctors hope for.
As a physician who studies early cancer detection, and as chair of the American Cancer Society’s screening guideline development group, I have been following this test’s development with interest.
While the Galleri test certainly shows great promise, clinical trial data indicates that it struggles with early-stage cancer detection and has not yet been shown to lower the risk of death from cancer or prevent advanced cancer. Across all cancer stages, the test missed over two-thirds of cancer cases.
On Sept. 23, 2026, an advisory panel to the U.S. Food and Drug Administration voted to recommend approval of the Galleri test. While a recommendation from the FDA’s advisory panel is not the same as full approval from the agency, it marks a critical first step in the process of potentially making the test widely available to the American public. The FDA has not yet announced when it will make a decision on the test.
But even as the advisory panel approved the test, panelists recommended that the word “early” be removed from “early cancer detection test” in product labeling. Panel members were not convinced the test can find cancers at their earliest and most curable stages, and they expressed uncertainty about the test’s benefit to patients at this time.
Given this uncertainty, careful scrutiny of the data behind the test can help doctors and patients make informed decisions about whether to use it.
What is the Galleri test? How does it work?Galleri is part of an emerging class of multicancer early detection tests. These tests do not diagnose cancer: If a test is positive, further evaluation is necessary to determine whether cancer is present, and, if so, what type of cancer. It is offered as a screening test, similar to mammography for breast cancer screening or PSA testing for prostate cancer screening, but with the potential advantage of screening for many cancers at once, including many for which no screening test currently exists.
The Galleri test looks for DNA fragments in blood that are associated with cancer. When something goes wrong with your DNA, whether because you inherited a mutation or something in your environment triggered that mutation, the processes that regulate cell division can go awry. Uncontrolled cell division can trigger the growth of cancer cells.
Galleri and other multicancer early detection tests in development look for differences that distinguish the DNA produced by tumor cells from normal cells. Galleri identifies unique tags on cancer DNA called methylation markers and uses machine learning algorithms to generate a positive or negative test result.
What are the strengths of the Galleri test?The Galleri test looks for DNA signals from over 50 cancers, including the 12 that account for almost two-thirds of cancer deaths in the U.S, such as lung and pancreas cancer. Importantly, it provides information on which organ the possible tumor likely originated from. Currently recommended cancer screenings are largely limited to four types of cancer.
Many of the cancers the Galleri test looks for are not currently included in routine screening. Moreover, the test has a very low false positive rate: Only about 0.5% of people who get the test are incorrectly identified as having cancer, or one person out of every 200 tests. A false positive rate is the percentage of people who are told they have cancer but actually don’t. This requires that patients get more testing, which can be costly, sometimes risky and often worrisome.
In comparison, many currently recommended screening tests, such as the Cologuard stool test for colorectal cancer, have false positive rates in the 10% range.
This very low false positive rate also translates into another strength – a very high positive predictive value, or PPV, which is the probability that a positive test result actually means cancer is present. The PPV of the Galleri test was 52% across three annual screens, meaning over half the positive results actually led to a cancer diagnosis. This is good because it gives people confidence that the test is more than 50% correct.
For context, the PPVs of most recommended screening tests—such as stool tests for colorectal cancer, mammography for breast cancer, or the HPV test for cervical cancer—are typically below 10%, meaning most positive results don’t lead to a cancer diagnosis.
The Galleri test also can predict with high accuracy where a cancer originated in the body. In one study of 32,000 U.S. adults age 50 and older who received a Galleri blood test, cancer was diagnosed in about 0.5% of them—173 patients. Of these patients, the test correctly predicted the cancer type in 91%. This specificity could help clinicians select more targeted evaluations rather than looking for cancer anywhere in the body.
What are the limitations of the Galleri test?Despite these impressive results, the Galleri test has several major shortcomings.
For one, the test is not as good at detecting cancer in its earliest stages as currently recommended screening tests, which is the main point of a cancer screening test. The test’s ability to detect cancer at all stages was less than 31% over three annual rounds of screening, meaning the test missed 69% of cases. Of the cancers detected in the study, comparing outcomes from getting the Galleri test three years in a row to routine cancer screening, 60% of the cancers detected in the people who got the Galleri test were early stage, which was almost identical to those who didn’t get it.
In addition, the Galleri test did not perform any better than standard screening tests at detecting cancer early. The detection rate for early-stage cancers was only 21% over three years of screening, meaning almost 80% were missed. Cancer is most curable in its early stages, so this shortcoming is a major one. Such a low detection rate can lead to false reassurance from an incorrectly negative test result.
Perhaps the most important shortcoming of the Galleri test is that it hasn’t yet proved that it can save lives or even reduce the risk of being diagnosed with late-stage cancer. The main goal of the trial was to show that the test could reduce the incidence of late-stage cancers over three years of screening—and it failed to do so. In other words, one of the hopes was that the test could reduce the risk of being diagnosed with advanced cancer by finding and treating cancer early—but as of now, there is no evidence to support this.
There was a hint that the incidence of Stage 4 cancer was trending lower by the third year of screening. But more time is needed to determine whether this is a true finding and, if so, whether it leads to a lower risk of dying from cancer.
Requests for comment from GRAIL were not returned.
What did the FDA’s panel recommend?The FDA advisory panel took three votes. While one of of these votes followed the evidence, two of them were surprisingly counterintuitive.
First, the panel voted 10-0 to recommend that the Galleri test is safe. While undergoing a blood test doesn’t typically involve any substantive risk, a positive result may prompt further testing, such as biopsies, that are riskier than a blood test and can incur additional costs.
These harms can be particularly hard to swallow if the test turns out to be a false alarm, as it will in about half of cases. One study evaluating Galleri’s safety found that 0.6% of those who had the test ended up undergoing an invasive diagnostic procedure, but none experienced serious complications. Hence, the safety vote appears to have been warranted.
Second, the panel voted 6-4 to recommend that the test is effective, though a number of the panelists cast their yes vote on the condition that the company remove the term “early” from the label “multi-cancer early detection” test.
This outcome, however, does not have the evidence to back it up. Available studies indicate the Galleri test does not reduce the incidence of late-stage cancer and performs poorly in detecting early-stage cancer. Additionally, there is no evidence that it lowers the risk of dying from cancer.
Finally, the panel voted 7-2 with one abstention to recommend that the benefits of the Galleri test outweigh the risk. But if there is no proven benefit to the test, how can the benefits outweigh the risks, even if the risk is low?
While the advisory panel acknowledged the test’s serious limitations, it still went ahead and recommended approval. One of the panel members stated that the ability to find more early-stage cancers in a broader population is a benefit, even though that hasn’t been proved yet. “So perhaps my ‘yes’ is a hopeful (vote) rather than an accurate one,” said the panel member.
The problem is that “hope” does not reduce death and disability from cancer.
Should you get the Galleri test or not?If the FDA agrees with its advisory panel’s recommendation and approves the Galleri test, it will likely be more widely marketed to the American public. Regardless, there remain many caveats, and I believe patients will want to be cautious.
First, FDA approval does not guarantee insurance coverage. The Centers for Medicare and Medicaid Services has a separate coverage determination process, and it is not required to grant coverage to FDA-approved tests. The out-of-pocket cost of the Galleri test is currently US$949.
It remains unclear whether the test can reduce your risk of dying from cancer or being diagnosed with advanced cancer. However, if you’re willing to pay the annual cost of the test, are willing to undergo further testing despite a high rate of false alarms, and are not overly reassured by a falsely negative test result, you can ask your doctor for more information about the test.
What doctors and researchers are certain about is the importance of staying up to date with currently recommended cancer screening tests for colon, breast, cervical and lung cancers, even if you decide to get the Galleri test. These tests are proven to detect early-stage cancer and lower your risk of dying from cancer. That’s the bottom line.
Andrew Wolf is a professor emeritus of medicine at the University of Virginia.
This article is republished from The Conversation under a Creative Commons license. Read the original article.
This new blood test claims to detect more than 50 cancers before the onset of symptoms
Cancer isn’t the leading cause of death in the United States; heart disease ranks first in that regard. But it’s cancer that strikes fear into the hearts of many Americans.
Cancer can take an excruciating toll on its millions of victims and their family members. Cancer treatments are often highly toxic, and the disease is increasingly striking people at younger ages, which is why it accounts for more years of potential life lost than heart disease.
So when a blood test comes along that claims to be able to screen for more than 50 cancers at once in a single blood draw before symptoms appear—as is the case for the Galleri test, by the biotech company GRAIL—it might seem like society has a Holy Grail of modern medicine at their fingertips.
But a closer look at the evidence suggests that the Galleri test is not yet the universal screening breakthrough patients and doctors hope for.
As a physician who studies early cancer detection, and as chair of the American Cancer Society’s screening guideline development group, I have been following this test’s development with interest.
While the Galleri test certainly shows great promise, clinical trial data indicates that it struggles with early-stage cancer detection and has not yet been shown to lower the risk of death from cancer or prevent advanced cancer. Across all cancer stages, the test missed over two-thirds of cancer cases.
On Sept. 23, 2026, an advisory panel to the U.S. Food and Drug Administration voted to recommend approval of the Galleri test. While a recommendation from the FDA’s advisory panel is not the same as full approval from the agency, it marks a critical first step in the process of potentially making the test widely available to the American public. The FDA has not yet announced when it will make a decision on the test.
But even as the advisory panel approved the test, panelists recommended that the word “early” be removed from “early cancer detection test” in product labeling. Panel members were not convinced the test can find cancers at their earliest and most curable stages, and they expressed uncertainty about the test’s benefit to patients at this time.
Given this uncertainty, careful scrutiny of the data behind the test can help doctors and patients make informed decisions about whether to use it.
What is the Galleri test? How does it work?Galleri is part of an emerging class of multicancer early detection tests. These tests do not diagnose cancer: If a test is positive, further evaluation is necessary to determine whether cancer is present, and, if so, what type of cancer. It is offered as a screening test, similar to mammography for breast cancer screening or PSA testing for prostate cancer screening, but with the potential advantage of screening for many cancers at once, including many for which no screening test currently exists.
The Galleri test looks for DNA fragments in blood that are associated with cancer. When something goes wrong with your DNA, whether because you inherited a mutation or something in your environment triggered that mutation, the processes that regulate cell division can go awry. Uncontrolled cell division can trigger the growth of cancer cells.
Galleri and other multicancer early detection tests in development look for differences that distinguish the DNA produced by tumor cells from normal cells. Galleri identifies unique tags on cancer DNA called methylation markers and uses machine learning algorithms to generate a positive or negative test result.
What are the strengths of the Galleri test?The Galleri test looks for DNA signals from over 50 cancers, including the 12 that account for almost two-thirds of cancer deaths in the U.S, such as lung and pancreas cancer. Importantly, it provides information on which organ the possible tumor likely originated from. Currently recommended cancer screenings are largely limited to four types of cancer.
Many of the cancers the Galleri test looks for are not currently included in routine screening. Moreover, the test has a very low false positive rate: Only about 0.5% of people who get the test are incorrectly identified as having cancer, or one person out of every 200 tests. A false positive rate is the percentage of people who are told they have cancer but actually don’t. This requires that patients get more testing, which can be costly, sometimes risky and often worrisome.
In comparison, many currently recommended screening tests, such as the Cologuard stool test for colorectal cancer, have false positive rates in the 10% range.
This very low false positive rate also translates into another strength – a very high positive predictive value, or PPV, which is the probability that a positive test result actually means cancer is present. The PPV of the Galleri test was 52% across three annual screens, meaning over half the positive results actually led to a cancer diagnosis. This is good because it gives people confidence that the test is more than 50% correct.
For context, the PPVs of most recommended screening tests—such as stool tests for colorectal cancer, mammography for breast cancer, or the HPV test for cervical cancer—are typically below 10%, meaning most positive results don’t lead to a cancer diagnosis.
The Galleri test also can predict with high accuracy where a cancer originated in the body. In one study of 32,000 U.S. adults age 50 and older who received a Galleri blood test, cancer was diagnosed in about 0.5% of them—173 patients. Of these patients, the test correctly predicted the cancer type in 91%. This specificity could help clinicians select more targeted evaluations rather than looking for cancer anywhere in the body.
What are the limitations of the Galleri test?Despite these impressive results, the Galleri test has several major shortcomings.
For one, the test is not as good at detecting cancer in its earliest stages as currently recommended screening tests, which is the main point of a cancer screening test. The test’s ability to detect cancer at all stages was less than 31% over three annual rounds of screening, meaning the test missed 69% of cases. Of the cancers detected in the study, comparing outcomes from getting the Galleri test three years in a row to routine cancer screening, 60% of the cancers detected in the people who got the Galleri test were early stage, which was almost identical to those who didn’t get it.
In addition, the Galleri test did not perform any better than standard screening tests at detecting cancer early. The detection rate for early-stage cancers was only 21% over three years of screening, meaning almost 80% were missed. Cancer is most curable in its early stages, so this shortcoming is a major one. Such a low detection rate can lead to false reassurance from an incorrectly negative test result.
Perhaps the most important shortcoming of the Galleri test is that it hasn’t yet proved that it can save lives or even reduce the risk of being diagnosed with late-stage cancer. The main goal of the trial was to show that the test could reduce the incidence of late-stage cancers over three years of screening—and it failed to do so. In other words, one of the hopes was that the test could reduce the risk of being diagnosed with advanced cancer by finding and treating cancer early—but as of now, there is no evidence to support this.
There was a hint that the incidence of Stage 4 cancer was trending lower by the third year of screening. But more time is needed to determine whether this is a true finding and, if so, whether it leads to a lower risk of dying from cancer.
Requests for comment from GRAIL were not returned.
What did the FDA’s panel recommend?The FDA advisory panel took three votes. While one of of these votes followed the evidence, two of them were surprisingly counterintuitive.
First, the panel voted 10-0 to recommend that the Galleri test is safe. While undergoing a blood test doesn’t typically involve any substantive risk, a positive result may prompt further testing, such as biopsies, that are riskier than a blood test and can incur additional costs.
These harms can be particularly hard to swallow if the test turns out to be a false alarm, as it will in about half of cases. One study evaluating Galleri’s safety found that 0.6% of those who had the test ended up undergoing an invasive diagnostic procedure, but none experienced serious complications. Hence, the safety vote appears to have been warranted.
Second, the panel voted 6-4 to recommend that the test is effective, though a number of the panelists cast their yes vote on the condition that the company remove the term “early” from the label “multi-cancer early detection” test.
This outcome, however, does not have the evidence to back it up. Available studies indicate the Galleri test does not reduce the incidence of late-stage cancer and performs poorly in detecting early-stage cancer. Additionally, there is no evidence that it lowers the risk of dying from cancer.
Finally, the panel voted 7-2 with one abstention to recommend that the benefits of the Galleri test outweigh the risk. But if there is no proven benefit to the test, how can the benefits outweigh the risks, even if the risk is low?
While the advisory panel acknowledged the test’s serious limitations, it still went ahead and recommended approval. One of the panel members stated that the ability to find more early-stage cancers in a broader population is a benefit, even though that hasn’t been proved yet. “So perhaps my ‘yes’ is a hopeful (vote) rather than an accurate one,” said the panel member.
The problem is that “hope” does not reduce death and disability from cancer.
Should you get the Galleri test or not?If the FDA agrees with its advisory panel’s recommendation and approves the Galleri test, it will likely be more widely marketed to the American public. Regardless, there remain many caveats, and I believe patients will want to be cautious.
First, FDA approval does not guarantee insurance coverage. The Centers for Medicare and Medicaid Services has a separate coverage determination process, and it is not required to grant coverage to FDA-approved tests. The out-of-pocket cost of the Galleri test is currently US$949.
It remains unclear whether the test can reduce your risk of dying from cancer or being diagnosed with advanced cancer. However, if you’re willing to pay the annual cost of the test, are willing to undergo further testing despite a high rate of false alarms, and are not overly reassured by a falsely negative test result, you can ask your doctor for more information about the test.
What doctors and researchers are certain about is the importance of staying up to date with currently recommended cancer screening tests for colon, breast, cervical and lung cancers, even if you decide to get the Galleri test. These tests are proven to detect early-stage cancer and lower your risk of dying from cancer. That’s the bottom line.
Andrew Wolf is a professor emeritus of medicine at the University of Virginia.
This article is republished from The Conversation under a Creative Commons license. Read the original article.
Today: CISO Forum Virtual Summit 2026 Day 2 – Join Cybersecurity Leaders Online
Designed for cybersecurity leaders, this immersive two-day virtual event is your premier destination to discuss, share, and learn innovative risk management and defense strategies defining the modern enterprise.
The post Today: CISO Forum Virtual Summit 2026 Day 2 – Join Cybersecurity Leaders Online appeared first on SecurityWeek.